Iqvia Q2 2018 earnings exceed expectations, CEO touts 'significant investments'

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/anyaberkut)
(Image: Getty/anyaberkut)

Related tags: IQVIA

Iqvia recently announced its second quarter 2018 results, which came in “above the high end” of the company’s expectations at $2.567bn, said CEO Ari Bousbib.

In response, the company raised its full year revenue guidance from a range of $10.05-10.25bn to a new range of $10.25bn to $10.40bn, which represents year-over-year growth of 5.6% to 7.2%.

The increase comes in response to organic operational strength, slightly more pass-through revenue in R&D Solutions than what was expected, and a higher contribution from M&A, said Michael McDonnell, EVP and CFO of Iqvia on the earnings call.

Adjusted EBITDA guidance also has been raised to represent a year-over-year growth of 8% to 10.9%.

Investments in innovation

Bousbib said business momentum has accelerated, driven by the strategic investments made over the past 18 months, noting that the company expects to continue such investment up until the end of 2019. “We've been making significant investments in innovation,”​ he said on the call.

As for the company’s technology business, Bousbib commented that it has won deals with Pierre Fabre, Recordati, and PruGen, among other clients in the US and Canada to deploy its commercial operations SaaS software, Orchestrated Customer Engagement (OCE). He also reported three new recent awards.

“When we decided to invest and innovate, our intent was to capture a fair share of this market,”​ Bousbib said. The offering was launched in 2017​.

Bousbib further emphasized the company’s goal of growing its technology business, calling the Iqvia “a technology company in aggregate.”

Overall, gross new business awards were up more than 40% compared to the same quarter last year, with more than 60% growth in the evidence-based practice (EBP) space. About 60% of the company’s next-gen awards in the second quarter were with EBP clients, Bousibib explained.

Additionally, the R&D business added more 150 new customers during the first half of 2018. 

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more